Dionex (NASDAQ:DNEX) to Continue Strong Organic Growth

Dionex (NASDAQ:DNEX) is expected to continue their strong organic growth narrative, according to Jefferies (NYSE:JEF), citing their continued focus on liquid chromatography analytical technologies.

Jefferies said, "DNEX's core focus in liquid chromatography analytical technologies, success in penetrating adjacent market niches, effective cost structure management, and disciplined capital re-deployment history have contributed to above-average organic revenue growth and profitability profiles and superior ROIC."

EPS estimates for full year 2011 and 2012 were maintained at $3.70 and $4.15.

Jefferies reiterates their "Hold" rating on Dionex, which closed Tuesday at $117.82, down $0.01, or 0.01 percent. They raised their price target on them from $100 to $118.50.

Thermo Fisher (NYSE:TMO) Up on Dionex (Nasdaq:DNEX) Bid

Thermo Fisher Scientific (NYSE:TMO) pushed up Monday on news of their Dionex (Nasdaq:DNEX) bid..

Auriga said, "DNEX has expanded its presence in China and India, and that both regions remain a key source of growth. DNEX's customers in emerging markets are generally "green field" opportunities -- as they have limited installed base or legacy equipment in house. As such, customers are often more open (or able) to exploring new product platforms."

DNEX had sales of $420 million for full year 2010, with 30 percent coming from HPLC and 70 percent from IC.

EPS estimates from Auriga for Thermo Fisher for full year 2011 are kept in place at $4.15.

Thermo Fisher closed Monday at $55.56, up $2.52, or 4.75 percent. Auriga has a price target of $66 on them.